Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) FCF Margin (2018 - 2025)

Serina Therapeutics' FCF Margin history spans 8 years, with the latest figure at 2941.54% for Q2 2025.

  • For Q2 2025, FCF Margin rose 1276238.0% year-over-year to 2941.54%; the TTM value through Sep 2025 reached 14237.93%, down 1385611.0%, while the annual FY2024 figure was 30575.0%, 3049508.0% down from the prior year.
  • FCF Margin for Q2 2025 was 2941.54% at Serina Therapeutics, down from 32550.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 32550.0% in Q4 2024 and bottomed at 32720.0% in Q1 2022.
  • The 5-year median for FCF Margin is 7850.0% (2021), against an average of 9307.2%.
  • The largest YoY upside for FCF Margin was 3253345bps in 2024 against a maximum downside of -2945667bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 6100.0% in 2021, then tumbled by -171bps to 16512.5% in 2022, then surged by 100bps to 16.55% in 2023, then skyrocketed by 196538bps to 32550.0% in 2024, then tumbled by -109bps to 2941.54% in 2025.
  • Per Business Quant, the three most recent readings for SER's FCF Margin are 2941.54% (Q2 2025), 32550.0% (Q4 2024), and 21178.57% (Q3 2024).